Journal of Molecular Modeling

, Volume 16, Issue 7, pp 1239–1249 | Cite as

Molecular docking and 3D-QSAR studies on β-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors

Original Paper

Abstract

Three-dimensional quantitative structure-activity relationship (3D-QSAR) and molecular docking studies were carried out to explore the binding of 73 inhibitors to dipeptidyl peptidase IV (DPP-IV), and to construct highly predictive 3D-QSAR models using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). The negative logarithm of IC50 (pIC50) was used as the biological activity in the 3D-QSAR study. The CoMFA model was developed by steric and electrostatic field methods, and leave-one-out cross-validated partial least squares analysis yielded a cross-validated value (\( {\hbox{r}}_{{\rm{cv}}}^{\rm{2}} \)) of 0.759. Three CoMSIA models developed by different combinations of steric, electrostatic, hydrophobic and hydrogen-bond fields yielded significant \( {\hbox{r}}_{{\rm{cv}}}^{\rm{2}} \) values of 0.750, 0.708 and 0.694, respectively. The CoMFA and CoMSIA models were validated by a structurally diversified test set of 18 compounds. All of the test compounds were predicted accurately using these models. The mean and standard deviation of prediction errors were within 0.33 and 0.26 for all models. Analysis of CoMFA and CoMSIA contour maps helped identify the structural requirements of inhibitors, with implications for the design of the next generation of DPP-IV inhibitors for the treatment of type 2 diabetes.

Figure

Binding conformations of docked compounds at the active site of dipeptidyl peptidase IV

Keywords

β-phenylalanine DPP-IV inhibitors CoMFA CoMSIA Molecular docking 3D-QSAR 

References

  1. 1.
    Mentlein R (1999) Regul Pept 85:9–24CrossRefGoogle Scholar
  2. 2.
    Hopsu-Havu VKGG (1966) Histochemie 7:197–201CrossRefGoogle Scholar
  3. 3.
    Holst JJ, Deacon CF (2004) Curr Opin Pharmacol 4:589–596CrossRefGoogle Scholar
  4. 4.
    Drucker DJ (2001) Curr Pharm Des 7:1399–1412CrossRefGoogle Scholar
  5. 5.
    Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Lancet 359:824–830CrossRefGoogle Scholar
  6. 6.
    Weber AE (2004) J Med Chem 47:4135–4141CrossRefGoogle Scholar
  7. 7.
    Deacon CF, Ahren B, Holst J (2004) J Exp Opin Investig Drugs 13:1091–1102CrossRefGoogle Scholar
  8. 8.
    Drucker D (2003) J Exp Opin Investig Drugs 12:87–100CrossRefGoogle Scholar
  9. 9.
    Augustyns K, Van der Veken P, Senten K, Haemers A (2003) Exp Opin Ther Patents 13:499–510CrossRefGoogle Scholar
  10. 10.
    Wiedeman PE, Trevillyan JM (2003) Curr Opin Investig Drugs 4:412–420Google Scholar
  11. 11.
    Barlocco D (2004) Curr Opin Investig Drugs 5:1094–1100Google Scholar
  12. 12.
    McIntyre JA, Castaner J (2004) Drugs Fut 29:887–891CrossRefGoogle Scholar
  13. 13.
    Holst JJ, Deacon CF (1998) Diabetes 47:1663–1670CrossRefGoogle Scholar
  14. 14.
    Augustyns K, Bal G, Thonus G, Belyaev A, Zhang XM, Bollaert W, Lambeir AM, Durinx C, Goossens F, Haemers A (1999) Curr Med Chem 6:311–327Google Scholar
  15. 15.
    Villhauer EB, Coppola GM, Hughes TE (2001) Annu Rep Med Chem 36:191–200CrossRefGoogle Scholar
  16. 16.
    Drucker DJ (2003) Exp Opin Investig Drugs 12:87–100CrossRefGoogle Scholar
  17. 17.
    Wiedeman PE, Trevillyan JM (2003) Curr Opin Investig Drugs 4:412–420Google Scholar
  18. 18.
    Villhauer EB, Brinkman JA, Naderi GB, Dunning BE, Mangold BL, Mone MD, Russell ME, Weldon SC, Hughes TE (2002) J Med Chem 45:2362–2365CrossRefGoogle Scholar
  19. 19.
    Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB (1999) Biochemistry 38:11597–11603CrossRefGoogle Scholar
  20. 20.
    Kanstrup AB, Christiansen LB, Lundbeck JM, Sams CK, Kristiansen M (2002) PCT Int Appl: WO2002002560Google Scholar
  21. 21.
    Sorbera LA, Revel L, Castaner J (2001) Drugs Fut 26:859–864CrossRefGoogle Scholar
  22. 22.
    Feng J, Gwaltney SL, Stafford JA, Zang Z (2005) Jpn Kokai Tokkyo Koho: JP 2005263780Google Scholar
  23. 23.
    Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE (2005) J Med Chem 48:141–151CrossRefGoogle Scholar
  24. 24.
    Mcintyre JA, Castaner J (2004) Drugs Fut 29:887–891CrossRefGoogle Scholar
  25. 25.
    Barlocco D (2004) Curr Opin Invest Drugs 5:1094–1100Google Scholar
  26. 26.
    Xu JY, Ok HO, Gonzalez EJ, Colwell LF, Habulihaz JB, He HB, Leiting B, Lyons KA, Marsilio F, Patel RA, Wu JK, Thornberry NA, Weber AE, Parmee ER (2004) Bioorg Med Chem Lett 14:4759–4762CrossRefGoogle Scholar
  27. 27.
    Brockunier LL, He JF, Colwell LF Jr, Habulihaz JB, He HB, Leiting B, Lyons KA, Marsilio F, Patel RA, Teffera Y, Wu JK, Thornberry NA, Weber AE, Parmee ER (2004) Bioorg Med Chem Lett 14:4763–4766CrossRefGoogle Scholar
  28. 28.
    Brandt W, Lehmann T, Barth A, Fittkaui S (1993) J Mol Graphics 11:277–278CrossRefGoogle Scholar
  29. 29.
    BrandtW LT, Thondor I, Born I, Schutkowski M, Rahfeld JU, Neubert K, Barth A (1995) Int J Peptide Prot Res 46:494–507CrossRefGoogle Scholar
  30. 30.
    Zeng J, Liu GX, Tang Y, Jiang HL (2007) J Mol Model 13:993–1000CrossRefGoogle Scholar
  31. 31.
    Pissurlenkar RRS, Shaikh MS, Coutinho EC (2007) J Mol Model 13:1047–1071CrossRefGoogle Scholar
  32. 32.
    Ashton WT, Sisco RM, Dong H, Lyons KA, He HB, Doss GA, Leiting B, Patel RA, Wu JK, Marsilio F, Thornberry NA, Weber AE (2005) Bioorg Med Chem Lett 15:2253–2258CrossRefGoogle Scholar
  33. 33.
    Kowalchick JE, Leiting B, Pryor KD, Marsilio F, Wu JK, He HB, Lyons KA, Eiermann GJ, Petrov A, Scapin G, Patel RA, Thornberry NA, Weber AE, Kim D (2007) Bioorg Med Chem Lett 17:5934–5939CrossRefGoogle Scholar
  34. 34.
    Chen P, Caldwell CG, Mathvink RJ, Leiting B, Marsilio F, Patel RA, Wu JK, He HB, Lyons KA, Thornberry NA, Weber AE (2007) Bioorg Med Chem Lett 17:5853–5857CrossRefGoogle Scholar
  35. 35.
    Kim D, Kowalchick JE, Edmondson SD, Mastracchio A, Xu J, Eiermann GJ, Leiting B, Wu JK, Pryor KD, Patel RA, He HB, Lyons KA, Thornberry NA, Weber AE (2007) Bioorg Med Chem Lett 17:3373–3377CrossRefGoogle Scholar
  36. 36.
    Kim D, Kowalchick JE, Brockunier LL, Parmee ER, Eiermann GJ, Fisher MH, He HB, Leiting B, Lyons KA, Scapin G, Patel SB, Petrov A, Pryor KD, Roy RS, Wu JK, Zhang XP, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE (2008) J Med Chem 51:589–602CrossRefGoogle Scholar
  37. 37.
    Sybyl Version 8.1 (2009) Tripos, St. Louis, MOGoogle Scholar
  38. 38.
    Clark M, Cramer RDI, Opdenbosch NV (1989) J Comput Chem 10:982–1012CrossRefGoogle Scholar
  39. 39.
    Gasteiger J, Marsili M (1980) Tetrahedron 36:3219–3228CrossRefGoogle Scholar
  40. 40.
    Weiner SJ, Kollman PA, Case DA, Singh C, Ghio G, Alagona S, Profeta P, Weiner P (1984) J Am Chem Soc 106:765–784CrossRefGoogle Scholar
  41. 41.
    Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) J Comput Chem 19:1639–1662CrossRefGoogle Scholar
  42. 42.
    Auffinger P, Hays FA, Westhof E, Ho PS (2004) Proc Natl Acad Sci USA 101:16789–16794CrossRefGoogle Scholar
  43. 43.
    Howard EI, Sanishvili R, Cachau RE, Mitschler A, Chevrier B, Barth P, Lamour V, Zandt MV, Sibley E, Bon C, Moras D, Schneider TR, Joachimiak A, Podjarny A (2004) Proteins 55:792–804CrossRefGoogle Scholar
  44. 44.
    Cramer RD, Patterson IIIDE, Bunce JD (1988) J Am Chem Soc 110:5959–5967CrossRefGoogle Scholar
  45. 45.
    Klebe G, Abraham U, Mietzner T (1994) J Med Chem 37:4130–4146CrossRefGoogle Scholar
  46. 46.
    Kuhn B, Hennig M, Mattei P (2007) Curr Top Med Chem 7:609–619CrossRefGoogle Scholar
  47. 47.
    Xu M, Zhang AQ, Han SK, Wang LS (2002) Chemosphere 48:707–715CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Research Center of Medical Chemistry and Chemical BiologyChongqing Technology and Business UniversityChongqingPeople’s Republic of China

Personalised recommendations